AbCellera Biologics (ABCL) Income from Continuing Operations: 2019-2024
Historic Income from Continuing Operations for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$162.9 million.
- AbCellera Biologics' Income from Continuing Operations fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
- As of FY2024, AbCellera Biologics' Income from Continuing Operations stood at -$162.9 million, which was down 11.24% from -$146.4 million recorded in FY2023.
- In the past 5 years, AbCellera Biologics' Income from Continuing Operations ranged from a high of $158.5 million in FY2022 and a low of -$162.9 million during FY2024.
- Its 3-year average for Income from Continuing Operations is -$50.2 million, with a median of -$146.4 million in 2023.
- As far as peak fluctuations go, AbCellera Biologics' Income from Continuing Operations spiked by 5,715.65% in 2020, and later plummeted by 192.35% in 2023.
- AbCellera Biologics' Income from Continuing Operations (Yearly) stood at $124.2 million in 2020, then grew by 23.60% to $153.5 million in 2021, then climbed by 3.29% to $158.5 million in 2022, then crashed by 192.35% to -$146.4 million in 2023, then dropped by 11.24% to -$162.9 million in 2024.